By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By Julie Steenhuysen CHICAGO, May 31 (Reuters) - Revolution Medicine's experimental pancreatic cancer pill doubled survival ...

A pill that doubles life expectancy in patients with pancreatic cancer has been hailed as the biggest breakthrough for ...

Revolution Medicines’ RVMD Phase 3 daraxonrasib data in metastatic pancreatic cancer cut death risk 60% and doubled ...

The highly anticipated results of a clinical trial for the pill, daraxonrasib, have been released, giving doctors hope for ...

A new drug for pancreatic cancer gives some hope for one of the most dire types of cancer. Copyright 2026 NPR The biggest portion of Boise State Public Radio's funding comes from readers like you who ...

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

Daraxonrasib, which nearly doubled patients' survival time, fights the disease in a new way. It bear-hugs a cancer protein that drives cell growth.

An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...